A new phase I/II study published in Radiotherapy and Oncology in September 2026 reports encouraging biochemical and imaging responses following prostate stereotactic ablative radiotherapy (SABR) with simultaneous focal dose escalation guided by prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI).
The study, titled “Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from the ARGOS-CLIMBER phase 1/2 trial,” was conducted by Yasir Alayed, Andrew Loblaw, Glenn S. Bauman, and colleagues from Canadian academic institutions.
Among 50 patients with unfavorable intermediate- to very-high-risk prostate cancer, the investigators observed high rates of biochemical response, increasing rates of complete response on PSMA PET, and generally favorable urinary and bowel quality-of-life outcomes.
However, one patient experienced a serious grade 4 gastrointestinal complication, highlighting the importance of careful treatment planning and long-term safety monitoring.
ARGOS-CLIMBER Trial Design and Patient Population
ARGOS-CLIMBER (NCT05269550) is a multi-institutional phase I/II clinical trial evaluating whether PSMA PET and multiparametric MRI can improve the precision of prostate SABR by identifying tumor regions suitable for simultaneous focal dose escalation.
The trial enrolled 50 patients, with a median age of 73 years.
The study population included:
- Unfavorable intermediate-risk prostate cancer: 23 patients (46%).
- High-risk prostate cancer: 23 patients (46%).
- Very-high-risk prostate cancer: 4 patients (8%).
Additionally, 10 patients (20%) had PSMA PET-positive regional lymph node involvement before treatment.
All patients underwent pretreatment ¹⁸F-PSMA PET/MRI using a hybrid 3-Tesla scanner.
Investigators used combined PET and MRI findings to define the dominant intraprostatic lesion, allowing focal radiation dose escalation to the imaging-defined tumor while treating the prostate and pelvic regions.
The primary endpoint was acute gastrointestinal and genitourinary toxicity. Secondary endpoints included quality of life, disease-free survival, overall survival, and biochemical and imaging biomarkers of treatment response.
PSMA PET and MRI Enable Simultaneous Focal Dose Escalation
The study used a five-fraction SABR schedule designed to deliver different radiation doses to the prostate, visible tumor, and pelvic lymph nodes.
The planned prescription included:
- Dominant intraprostatic lesion: Target dose of 50 Gy in five fractions, subject to organ-at-risk constraints.
- Whole prostate: 35 Gy in five fractions.
- Elective pelvic regions: 25 Gy in five fractions.
- PSMA PET-positive lymph nodes: 35 Gy in five fractions.
Treatment was delivered using volumetric modulated arc therapy (VMAT) on alternate days.
Importantly, although the focal boost prescription targeted 50 Gy, normal tissue constraints were prioritized.
Consequently, the actual median delivered dose to the dominant intraprostatic lesion was 44.1 Gy, with a mean dose of 43.9 Gy.
All patients also received androgen deprivation therapy (ADT) following SABR, generally for six months in unfavorable intermediate-risk disease and 18 months in high-risk disease.
The combined approach was designed to intensify treatment in imaging-defined tumor regions while limiting radiation exposure to surrounding organs.
Complete Response Rates Increase on PSMA PET and MRI
Following treatment, the investigators observed progressive improvements in imaging-based tumor response.
At six months, complete response on PSMA PET was documented in 25.5% (12/47) of evaluable patients.
By two years, the PSMA PET complete response rate increased to 66% (27/41).
MRI findings demonstrated a similar pattern.
The proportion of patients with negative MRI findings increased from 38% (18/47) at six months to 57% (24/42) at two years.
These results suggest that imaging changes following prostate SABR may continue to evolve well beyond the early post-treatment period.
Biochemical responses were also favorable. Mean PSA decreased from approximately 15.4 ng/mL at baseline to 0.18 ng/mL at six months and remained approximately 0.19 ng/mL at 24 months.
However, PSA responses must be interpreted in the context of concomitant ADT, which contributes substantially to PSA suppression.
Importantly, no isolated local failures were observed during the reported follow-up.
Post-Treatment Biopsies Reveal Important Differences Between Imaging and Pathology
A particularly interesting finding emerged from the optional two-year prostate biopsies.
Twelve patients underwent follow-up biopsy, of whom:
- Eight had negative biopsies.
- Four had persistent prostate cancer with treatment effect.
All four patients with persistent cancer on biopsy demonstrated complete response on PSMA PET.
Among the 12 biopsied patients, 11 had complete PSMA PET responses, while one demonstrated a partial response with low-grade residual uptake despite a negative biopsy.
These findings highlight an important limitation of imaging-based response assessment.
Complete response on PSMA PET does not necessarily indicate complete pathological eradication of prostate cancer.
However, the significance of residual tumor showing treatment effect requires careful interpretation, particularly because the study did not establish whether these findings would translate into subsequent local recurrence.
Only 12 of the 50 enrolled patients underwent biopsy, limiting the ability to determine the accuracy of PSMA PET or MRI for predicting pathological response.
Favorable Disease Control and Survival Outcomes
After a median follow-up of approximately three years, two patients experienced biochemical failure in the setting of metastatic progression.
These events occurred at 12 and 24 months following treatment.
Both patients subsequently died from progressive prostate cancer.
Three additional patients died from causes unrelated to prostate cancer.
The estimated three-year overall survival was 88.9% (95% CI, 75.2–95.3%).
Three-year prostate cancer-specific survival reached 95.7% (95% CI, 83.8–98.9%).
Although these findings are encouraging, the small sample size and limited number of events prevent definitive conclusions regarding long-term disease control.
Furthermore, the single-arm study design does not establish whether PSMA PET/MRI-guided focal boosting improves survival compared with conventional prostate SABR.
Late Toxicity and Quality-of-Life Outcomes
The updated analysis demonstrated generally favorable late genitourinary and gastrointestinal toxicity outcomes.
Late grade 2 genitourinary adverse events occurred in five patients (10%).
No late grade 3 or 4 genitourinary adverse events were reported.
No late grade 2 or 3 gastrointestinal events were observed.
However, one patient experienced a grade 4 gastrointestinal complication requiring colostomy.
This patient had locally advanced disease with seminal vesicle involvement and initially developed mild rectal bleeding.
Endoscopy demonstrated mild proctitis and an angiodysplastic lesion, which was treated with argon plasma coagulation.
Approximately one week later, the patient developed an anterior rectal wall defect requiring colostomy.
The investigators noted that the complication could have been partly related to the endoscopic intervention.
The event nevertheless emphasizes the potential severity of rectal complications following prostate dose escalation and the importance of cautious management of post-radiotherapy rectal bleeding.
Patient-reported quality of life was evaluated using EPIC-26.
At two years, mean changes from baseline were relatively small across several domains:
- Urinary irritative/obstructive function: +3.4 points.
- Urinary incontinence: −3.7 points.
- Bowel function: −4.3 points.
These findings suggest generally preserved urinary and bowel quality of life among evaluable patients, although sexual and hormonal outcomes were also influenced by ADT.
Can Imaging Biomarkers Help Personalize Future Prostate Radiotherapy?
The investigators explored whether radiation dose and anatomical factors were associated with complete response on PSMA PET.
At six months, lower bladder and urethral planning organ-at-risk volume doses were associated with a greater likelihood of PET complete response.
Higher intraprostatic boost dose also showed a positive trend.
However, at two years, none of the evaluated predictors reached conventional statistical significance.
The authors suggested that lesion location, proximity to critical organs, and the ability to deliver higher focal doses may influence treatment response.
These analyses were exploratory and involved a limited sample size, preventing definitive conclusions.
Nevertheless, combining PSMA PET, MRI, PSA kinetics, and pathological evaluation may eventually help identify patients who could benefit from treatment intensification or de-escalation.
What Do These Findings Mean for Clinical Practice?
The ARGOS-CLIMBER trial contributes to the growing evidence supporting focal dose escalation during prostate SABR, particularly in patients with unfavorable intermediate- and high-risk disease.
Unlike approaches relying on MRI alone, this strategy combines PSMA PET and MRI to define tumor targets and includes simultaneous treatment of elective pelvic lymph nodes and PET-positive nodal disease.
The results demonstrate encouraging biochemical and imaging responses with generally acceptable toxicity.
However, several limitations remain.
The study included only 50 patients and lacked a randomized control group.
The median follow-up of three years remains insufficient to establish long-term biochemical control or late toxicity, particularly in higher-risk prostate cancer.
The use of ADT also complicates interpretation of PSA kinetics and imaging responses.
Additionally, the serious grade 4 gastrointestinal event highlights the need for careful organ-at-risk constraints and long-term follow-up.
Perhaps most importantly, the discordance between complete PSMA PET response and persistent tumor on biopsy demonstrates that imaging responses cannot yet replace validated clinical endpoints or pathological assessment.
Moving Toward Imaging-Guided Personalized Prostate SABR
The ARGOS-CLIMBER trial demonstrates the feasibility of combining PSMA PET and MRI-guided focal boosting with five-fraction prostate and pelvic SABR.
At two years, 66% of evaluable patients achieved complete response on PSMA PET, 57% had negative MRI findings, and no isolated local failures were reported.
The study also demonstrated generally preserved urinary and bowel quality of life, although one serious gastrointestinal complication occurred.
These findings support further investigation of PSMA PET/MRI-guided dose escalation as a personalized radiotherapy strategy for patients with unfavorable intermediate- and high-risk prostate cancer.
Longer follow-up and randomized comparisons will be required to determine whether this approach improves durable disease control and whether combined imaging biomarkers can reliably identify patients suitable for treatment escalation or de-escalation.
Read full article here.